Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Crash diet
Mechanism of Action Triple receptor co-agonism: GLP-1R for appetite suppression and incretin effect, GIPR for improved insulin sensitivity, glucagon receptor for increased energy expenditure and hepatic fat oxidation addressing obesity through three distinct metabolic pathways simultaneously Target: GLP-1 receptor (GLP1R), GIP receptor (GIPR), Glucagon receptor (GCGR) Clinical trials demonstrate significant body weight reduction with sustained benefit Improves glycemic control and A1C levels in type 2 diabetes Associated with reduced cardiovascular events in high-risk patients Addresses multiple components of metabolic syndrome simultaneously These are commonly discussed research protocols not medical advice
These could be signs of an allergic reaction
This triple target is a big leap from previous launches like semaglutide and tirzepatide, which only directed one or two of these identical hormone paths
US$ 29.71
US$ 23.55
US$ 21.12
US$ 25.58
US$ 23.81
US$ 21.78
US$ 20.06
US$ 25.53
US$ 23.36
US$ 24.05
